MiR-335 inhibits migration of breast cancer cells through targeting oncoprotein c-Met

Tumor Biology

Volumn 36, Issue 4, 2015, Pages 2875-2883

  Gao, Yue ^a   Zeng, Fan ^a   Wu, Jia Yan ^a   Li, Hai Yu ^a   Fan, Jian Jun ^a   Mai, Li ^a   Zhang, Ji ^a   Ma, Dong Mei ^a   Li, Yun ^a   Song, Fang zhou ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

5 AZA CdR; Breast cancer; c Met; HGF; Metastasis; miR 335

Indexed keywords

AZACITIDINE; DECITABINE; MICRORNA; MIRN335 MICRORNA, HUMAN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BREAST TUMOR; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; TUMOR INVASION;

AZACITIDINE; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HUMANS; MCF-7 CELLS; MICRORNAS; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-MET;

EID: 84936768769     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2917-6     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.
2. Weigelt B, Peterse JL, van’t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5:591–602.
3. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.
4. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N. Croce CM: Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A. 2006;103:7024–9.
5. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303:83–6.
6. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle specific microRNA that targets Hand2 during cardiogenesis. Nature. 2005;436:214–20.
7. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. Croce CM: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005;102:13944–9.
8. Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.
9. Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451:147–52.
10. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell. 2009;137:1032–46.
11. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. Weinberg RA: miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010;12:247–71.
12. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449:682–8.
13. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915–25.
14. Benvenuti S, Comoglio PMJ. The MET receptor tyrosine kinase in invasion and metastasis. Cell Physiol. 2007;213:316–25.
15. Leelawat K, Leelawat S, Tepaksorn P, Rattanasinganchan P, Leungchaweng A, Tohtong R, et al. Involvement of c-Met/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met. J Surg Res. 2006;136:78–84.
16. Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R, et al. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer. 2007;97:368–77.
17. Sipeki S, Bander E, Buday L, Farkas G, Bácsy E, Ways DK, et al. Phosphatidylinositol 3-kinase contributes to Erk1/Erk2 MAP kinase activation associated with hepatocyte growth factor-induced cell scattering. Cell Signal. 1999;11:885–90.
18. Wu ZS, Wu Q, Wang CQ, Wang XN, Huang J, Zhao JJ, et al. Zhang N: miR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met. Cancer. 2011;117:2842–52.
19. Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 2009;275:44–53.
20. Tan S, Li R, Ding K, Lobie PE, Zhu T. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Lett. 2011;585:2229–34.
21. Krek A et al. Combinatorial microRNA target predictions. Nat Genet. 2005;37:495–500.
22. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20.
23. Naldidi L, Vigna E, Narsimhan R, et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the protooncogene c-MET. Oncogene. 1991;6:501–4.
24. Momparler RL. Epigenetic therapy of cancer with 5-aza-2′-deoxycytidine (decitabine). Semin Oncol. 2005;32:443–51.
25. Png KJ, Yoshida M, Zhang XH, et al. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev. 2011;25:226–31.
26. Tuck AB, Park M, Sterns EE, Boag A, Elliott BE. Coexpression of hepatocyte growth factor and receptor (met) in human breast carcinoma. Am J Pathol. 1996;148:225–32.
27. Beviglia L, Matsumoto K, Lin CS, Ziober BL, Kramer RH. Expression of the c-met/HGF receptor in human breast carcinoma: correlation with tumor progression. Int J Cancer. 1997;74:301–9.
28. Gherardi E, Stoker M. Hepatocyte and scatter factor. Nature. 1990;346:228.
29. Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res. 2006;12:3657–60.
30. Garcia S, Dales JP, Charafe-Jauffret E, et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol. 2007;38:830–41.
31. Jiang WG, Grimshaw D, Lane J, et al. A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c- MET and reduces migration and invasiveness of breast cancer cells. Clin Cancer Res. 2001;7:2555–62.
32. Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/c-MET signalling pathway in cancer. Eur J Cancer. 2010;46:1260–70.